SCHEMBL7918197

SCHEMBL7918197

N#CC(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 2/20 0.61
CA1 P00915 2/20 0.59
CA2 P00918 2/20 0.59
TDP1 Q9NUW8 1/20 0.59
ALDH1A1 P00352 3/20 0.57
TSHR P16473 1/20 0.57
MAPK1 P28482 1/20 0.57
MAPT P10636 2/20 0.56
MEN1 O00255 1/20 0.56
HSP90AA1 P07900 1/20 0.56
OPRK1 P41145 1/20 0.56
KMT2A Q03164 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
KDM4E B2RXH2 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
CES2 O00748 1/20 0.53
SRD5A2 P31213 1/20 0.53
GSK3B P49841 1/20 0.52
LMNA P02545 1/20 0.52
GAA P10253 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9132299 0.80 CES1 (0.61) CES1CA1CA2TDP1ALDH1A1
SCHEMBL10719753 0.80 GSK3B (0.43) CA1CA2TDP1ALDH1A1TSHR
SCHEMBL10925104 0.80 CYP3A4 (0.57) CES1ALDH1A1TSHRMEN1KMT2A
SCHEMBL14790553 0.79 CES1 (0.50) CES1CA1CA2TDP1ALDH1A1
SCHEMBL4399847 0.78 CES1 (0.53) CES1CA1CA2TDP1ALDH1A1
SCHEMBL29410421 0.78 CES1 (0.53) CES1CA1CA2TDP1ALDH1A1
SCHEMBL5150143 0.78 CES2 (0.66) CES1ALDH1A1TSHRMAPTMEN1
SCHEMBL6604503 0.77 ALDH1A1 (0.61) CES1CA1CA2TDP1ALDH1A1
SCHEMBL4474269 0.77 TDP1 (0.55) CES1CA1CA2TDP1ALDH1A1
SCHEMBL12808198 0.77 CES1 (0.57) CES1CA1CA2TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4596885-A Process for the preparation of phenylglyoxylic acid esters BAYER AKTIENGESELLSCHAFT (DE) 1986-06-24 US claimed
US-RE46144-E1 Hydroxamic acid derivatives PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) 2016-09-13 US disclosed
US-RE46144-E1 Hydroxamic acid derivatives PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) 2016-09-13 US disclosed
US-9096627-B2 Hydroxamic acid derivatives PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) 2015-08-04 US disclosed
US-9096627-B2 Hydroxamic acid derivatives PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) 2015-08-04 US disclosed
US-20140066419-A1 HYDROXAMIC ACID DERIVATIVES PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) 2014-03-06 US disclosed
US-20140066419-A1 HYDROXAMIC ACID DERIVATIVES PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) 2014-03-06 US disclosed
US-20110269706-A1 Hydroxamic Acid Derivatives NORTHLAKE BIOSCIENCES LLC (US) 2011-11-03 US disclosed
US-20110269706-A1 Hydroxamic Acid Derivatives NORTHLAKE BIOSCIENCES LLC (US) 2011-11-03 US disclosed
WO-2010085377-A2 HYDROXAMIC ACID DERIVATIVES CRYSTAL BIOPHARMACEUTICAL LLC (US) 2010-07-29 WO disclosed
EP-0010652-B1 4-CHLOROOXAZOLES, METHOD FOR THEIR PREPARATION AND THEIR USE IN PHOTOCONDUCTIVE COATINGS IN ELECTROPHOTOGRAPHY AND AS OPTICAL BRIGHTENERS HOECHST AKTIENGESELLSCHAFT (DE) 1983-05-18 EP disclosed
US-4371606-A 2-(Halogenomethyl-phenyl)-4-halogeno-oxaxole derivatives, a process for the preparation thereof, and radiation-sensitive compositions containing these derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1983-02-01 US disclosed
EP-0041674-A2 2-(Trichloro-methyl-phenyl)-4-halogen-oxazole derivatives, process for preparing them and radiation-sensitive compositions containing them HOECHST AKTIENGESELLSCHAFT (DE) 1981-12-16 EP disclosed
US-4294760-A Preparation of 5-(arylcyanohydroxymethyl)-1-loweralkylpyrrole-2-acetic acid derivatives MCNEILAB, INC. (US) 1981-10-13 US disclosed
US-4255335-A Preparation of 5-aroyl-1-loweralkylpyrrole-2-acetic acid derivatives MCNEILAB, INC. (US) 1981-03-10 US disclosed
US-4238412-A CYANATION OF THE ANHYDRIDE BAYER AKTIENGESELLSCHAFT (DE) 1980-12-09 US disclosed
EP-0010652-A1 4-Chlorooxazoles, method for their preparation and their use in photoconductive coatings in electrophotography and as optical brighteners HOECHST AKTIENGESELLSCHAFT (DE) 1980-05-14 EP disclosed
US-4122116-A HERBICIDES DEUTSCHE GOLD- UND SILBER- SCHEIDEANSTALT VORMALS ROESSLER (DE) 1978-10-24 US disclosed
US-4108877-A REACTING ACYL HALIDE WITH COPPER CYANIDE WITH HEATING IN THE PRESENCE OF A CARBOXYLIC ACID NITRILE AND AN ORGANIC SOLVENT DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) 1978-08-22 US disclosed
US-4108875-A REACTING ACYL HALIDE WITH AN ALKALI METAL CYANIDE AND A COPPER(I) SALT IN THE PRESENCE OF A CARBOXYLIC ACID NITRILE WITH HEATING DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) 1978-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066419-A1 HYDROXAMIC ACID DERIVATIVES HDAC5, HDAC7, HDAC4 CES1 965/4885CA1 30/4885CA2 20/4885
US-20110269706-A1 Hydroxamic Acid Derivatives CD74, HLA-DRB1, HDAC5 CES1 1539/4885CA1 65/4885CA2 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.